• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

17

CATEGORIES

  • 9
  • 3
  • 3
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1

PRICE

10
12
15
23

PUBLISHED

0
0
4
23

PRODUCT TYPE

19
3
1

Search "Schering-Plough: Pipeline - Products - Performance - Potential" returned 23 results.

PRODUCT TITLE
The Asthma and COPD Market Outlook: Market Analysis of Future Growth and Leading Players by Sector The Asthma and COPD Market Outlook: Market Analysis of Future Growth and Leading Players by Sector - Product Thumbnail Image

The Asthma and COPD Market Outlook: Market Analysis of Future Growth and Leading Players by Sector

In terms of revenue, the asthma and COPD therapeutic area historically ranks as the sixth largest single source of sales for the pharmaceutical industry. The outlook for the market is currently strong,...

January 2005
FROM
The Cancer Market Outlook to 2010 The Cancer Market Outlook to 2010 - Product Thumbnail Image

The Cancer Market Outlook to 2010

The cancer market has undergone a high degree of innovation led change over the previous five years, which has created strong opportunities for a range of established and emerging biotechnology and...

November 2005
FROM
Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI - Product Thumbnail Image

Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI

Offshoring and outsourcing have become an increasingly critical contributor to pharma and biotech R&D strategies in recent years They enable companies to focus on core competencies such as drug discovery...

March 2009
FROM

Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential

“Big Pharma's Key Lifecycle Management Strategies: Maximizing the Market Potential ” provides key data, information and analysis on the key lifecycle management strategies implemented by pharmaceutical...

February 2010
FROM

Tildrakizumab (Psoriasis) - Forecast and Market Analysis to 2022

Tildrakizumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2–3% worldwide...

May 2013
FROM
Innovative and Targeted Cancer Therapies: Key Technologies, New Applications and Leading Players Innovative and Targeted Cancer Therapies: Key Technologies, New Applications and Leading Players - Product Thumbnail Image

Innovative and Targeted Cancer Therapies: Key Technologies, New Applications and Leading Players

This portfolio of healthcare management reports are designed to help you make well informed and timely business decisions We understand the problems facing today's pharmaceutical and healthcare executives...

July 2007
FROM
The Global Cancer Vaccine Market, 2nd Edition: Pipeline Analysis and Future Market Impact The Global Cancer Vaccine Market, 2nd Edition: Pipeline Analysis and Future Market Impact - Product Thumbnail Image

The Global Cancer Vaccine Market, 2nd Edition: Pipeline Analysis and Future Market Impact

In 2010, the therapeutic cancer vaccine market witnessed several key milestones Dendreon's Provenge (sipuleucel-T) became the first product to reach the market; gaining long-awaited FDA approval for...

January 2011
FROM

Prefilled Syringes Market, 2013 - 2023

Prefilled syringes are gaining strong acceptance in the market as drug delivery systems for injectable drugs They have become a preferred device for parenteral administration of drugs, mainly used for...

July 2013
FROM

The Medicines Company (MDCO) - Financial and Strategic SWOT Analysis Review

Summary The Medicines Company (TMC) is a pharmaceutical company providing medical solutions for improving health conditions in critical care patients. The product portfolio of the company comprises...

March 2013
FROM

Vivus, Inc. (VVUS) - Financial and Strategic SWOT Analysis Review

Summary Vivus Inc. (Vivus) is a biopharmaceutical company. It develops and commercializes therapies that address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's product...

May 2013
FROM

Agenix Limited (AGX) - Financial and Strategic SWOT Analysis Review

Agenix Limited (AGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData...

January 2014
FROM
The Rheumatoid Arthritis Market - Competitive Landscape and Clinical Stage Analysis The Rheumatoid Arthritis Market - Competitive Landscape and Clinical Stage Analysis - Product Thumbnail Image

The Rheumatoid Arthritis Market - Competitive Landscape and Clinical Stage Analysis

Overview Rheumatoid arthritis, a systemic disease characterized by inflammation of the membrane lining the joint, is one of the most common forms of arthritis Up to 50 percent of all rheumatoid arthritis...

May 2009
FROM
The Rheumatoid Arthritis Market: Competitive Landscape and Clinical Stage Analysis The Rheumatoid Arthritis Market: Competitive Landscape and Clinical Stage Analysis - Product Thumbnail Image

The Rheumatoid Arthritis Market: Competitive Landscape and Clinical Stage Analysis

Rheumatoid arthritis, a systemic disease characterized by inflammation of the membrane lining the joint, is one of the most common forms of arthritis Up to 50 percent of all rheumatoid arthritis patients...

May 2009
FROM
Dyslipidemia: Opportunities in Cardiovascular Risk Reduction Dyslipidemia: Opportunities in Cardiovascular Risk Reduction - Product Thumbnail Image

Dyslipidemia: Opportunities in Cardiovascular Risk Reduction

This report examines trends in the dyslipidemia market, which is poised for transformation with the advent of novel combination products and biopharmaceuticals Cholesterol (LDL and HDL) and triglycerides...

July 2008
Inhibitex, Inc. (INHX) - Financial and Strategic Analysis Review Inhibitex, Inc. (INHX) - Financial and Strategic Analysis Review - Product Thumbnail Image

Inhibitex, Inc. (INHX) - Financial and Strategic Analysis Review

Inhibitex, Inc. (Inhibitex) is a development stage biopharmaceutical company engaged in the research and development of innovative products for the treatment of serious infectious diseases. The pipeline...

July 2010
FROM
Colorectal Cancer (CRC) Therapeutics - Global Strategic Business Report Colorectal Cancer (CRC) Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Colorectal Cancer (CRC) Therapeutics - Global Strategic Business Report

This report analyzes the worldwide markets for Colorectal Cancer Therapeutics in US$ Million The major product segments analyzed are Cytotoxic Therapies (5-FU (Fluorouracil), Camptosar (Irinotecan),...

October 2006
FROM
2010 Midyear Outlook: Global Credit Markets May Be At An Inflection Point Jul 10 2010 Midyear Outlook: Global Credit Markets May Be At An Inflection Point Jul 10 - Product Thumbnail Image

2010 Midyear Outlook: Global Credit Markets May Be At An Inflection Point Jul 10

Abstract As part of a roundtable discussion to discuss the prospects facing the credit markets for the remainder of 2010 and into 2011, some of Standard & Poor's Ratings Services' top analysts addressed...

July 2010
2010 Midyear Outlook: Global Credit Markets May Be At An Inflection Point Jul 10 2010 Midyear Outlook: Global Credit Markets May Be At An Inflection Point Jul 10 - Product Thumbnail Image

2010 Midyear Outlook: Global Credit Markets May Be At An Inflection Point Jul 10

Abstract As part of a roundtable discussion to discuss the prospects facing the credit markets for the remainder of 2010 and into 2011, some of Standard & Poor's Ratings Services' top analysts addressed...

July 2010
Credit Trends: Downgrade Potential Across Credit Grades And Sectors Feb 06 Credit Trends: Downgrade Potential Across Credit Grades And Sectors Feb 06 - Product Thumbnail Image

Credit Trends: Downgrade Potential Across Credit Grades And Sectors Feb 06

Abstract A total of 636 entities appeared at risk globally of potential downgrades as of Feb. 22, 2006, compared with 620 in mid-January. Almost 87% of those at risk of downgrades were located either...

February 2006
Credit Trends: Downgrade Potential Across Credit Grades And Sectors Oct 05 Credit Trends: Downgrade Potential Across Credit Grades And Sectors Oct 05 - Product Thumbnail Image

Credit Trends: Downgrade Potential Across Credit Grades And Sectors Oct 05

Abstract A total of 649 entities appeared at risk globally of potential downgrades as of Oct. 26, 2005, compared with 632 in mid-September. 88% of those at risk of downgrades were located either in...

October 2005
Loading Indicator